Bailador Technology Investments Ltd is an investment company. The company invests in Information Technology businesses. Its objective is to deliver long-term absolute returns to shareholders. It operates in Australia and New Zealand. The company's portfolio consists of SiteMinder, Access Telehealth, RC TopCo, Nosto, Hapana, Rosterfy, Updoc, and others.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
100.0%
暂无批准数据
- British American Tobacco has halted the pilot launch of its unlicensed Vuse One vape in the United States due to intensified FDA regulatory enforcement. - The decision reflects growing challenges for major tobacco companies competing in the $22 billion U.S. smoking alternatives market amid an influx of unlicensed products from China. - Philip Morris International has expressed similar concerns about launching unlicensed products in the current tightening regulatory environment. - Industry stakeholders continue to lobby for FDA licensing process reforms while navigating complex regulatory frameworks for nicotine alternatives.
- The FDA will expedite reviews of nicotine pouches from four major tobacco companies through a pilot program launching Monday, aiming to complete reviews by December. - The initiative follows pressure from Trump administration leadership to accelerate the approval process for smoking alternatives, with companies previously waiting years for product clearance. - Products from Philip Morris International, Altria, Reynolds American, and Turning Point Brands will undergo streamlined reviews focusing on essential scientific data and manufacturing consistency.
- Singapore has officially launched the non-GMP NATi mRNA BioFoundry, Asia's first dedicated mRNA manufacturing facility, marking a significant advancement in the country's nucleic acid therapeutics capabilities. - The $97 million facility, developed through collaboration between NATi, A*STAR, and Wellcome Leap, features automated manufacturing processes that enhance productivity and reduce production costs for mRNA-based products. - While currently focused on research and preclinical production, the BioFoundry is designed to rapidly scale up during health emergencies, potentially producing up to 20 billion doses of RNA-based vaccines monthly during outbreaks.
- Jazz Pharmaceuticals' Epidyolex did not meet its primary endpoint in a Phase 3 trial in Japan for treatment-resistant epilepsies, despite showing numeric improvements. - The trial assessed Epidyolex as an adjunctive treatment for Dravet Syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in pediatric patients. - British American Tobacco's cannabis investments are expected to drive growth, offsetting declines in traditional tobacco revenues through strategic investments like Organigram. - DanCann Pharma reported record revenue and its first positive EBITDA in Q2 2024, driven by increased product sales and strategic cost management.
